STAT

Opinion: A scientist opened up about his tough road to a Ph.D. It triggered a wave of responses

A scientist opened up in a recent First Opinion about his tough road to a Ph.D. It triggered a wave of responses from current and former grad students and postdocs.

An “escape from living a normal, mundane life,” is how one reader called her lab research as a grad student. Another mentioned the “moments of wonder that punctuated the darkness.” Yet another “started grad school with enthusiasm and ended, like most people I knew, slightly bitter and just wanting the pain to end.”

The responses to Justin Chen’s First Opinion essay, “Coming to terms with six years in science: obsession, isolation, and moments of wonder,” were as varied and nuanced as the article. Submitted by current and former bioscience graduate students and postdocs, they suggest that Chen’s piece touched a nerve among this large community.

Here is a sampling of reader responses to the article, lightly edited for clarity.

Helen K.

I had just about the same experience — family, friends, and physical/mental health falling by by the wayside — except that I was very lucky to have had an amazing husband who was able to stick it out with me. This is the most honest and captivating writing I have seen on the subject — probably because it mirrored my experience so closely. For a long time, I feared that my Ph.D. journey had broken me — but now that I have been away from the bench for a while, I also feel nostalgic about the “moments of wonder” that punctuated the

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A 486% Drug Price Hike, AstraZeneca CEO Pay, And More
Is there any circumstance when a 486% increase for a medicine might be justified? A small company called Harrow argues the case for an injectable eye treatment.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks